Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

医学 多发性骨髓瘤 生活质量(医疗保健) 耐火材料(行星科学) 内科学 儿科 肿瘤科 护理部 物理 天体生物学
作者
Michel Delforge,Krina K. Patel,Laurie Eliason,Devender S. Dhanda,Ling Shi,Shien Guo,Thomas S. Marshall,Bertrand Arnulf,Michèle Cavo,Ajay K. Nooka,Salomon Manier,Natalie S. Callander,Sergio Giralt,Hermann Einsele,Sikander Ailawadhi,Mihaela Popa McKiver,Mark A. Cook,Paula Rodríguez‐Otero
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (3): e216-e227 被引量:36
标识
DOI:10.1016/s2352-3026(24)00005-x
摘要

Background Chimeric antigen receptor T-cell therapy idecabtagene vicleucel (ide-cel) showed significantly improved progression-free survival compared with standard regimens in adults with relapsed and refractory multiple myeloma who had received two to four previous regimens in the ongoing phase 3 KarMMa-3 trial (NCT03651128). This study analysed patient-reported outcomes (PROs), a KarMMa-3 secondary endpoint. Methods In the randomised, open-label, phase 3 KarMMa-3 trial, 386 patients in hospitals (≥18 years of age, with measurable disease and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who had received two to four previous regimens—including an immunomodulatory agent, a proteasome inhibitor, and daratumumab—and had documented disease progression after receiving their last dose of the last therapy) were randomly assigned to ide-cel (n=254) or standard regimens (daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib, and dexamethasone; ixazomib, lenalidomide, and dexamethasone; carfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone; n=132). Patients were expected to complete the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life C30 Questionnaire (QLQ-C30), Multiple Myeloma Module (QLQ-MY20), EQ 5 dimensions (EQ-5D), and EQ-5D visual analogue scale (VAS) at baseline and follow-up timepoints (data cutoff April 18, 2022). PROs included nine prespecified primary domains: EORTC QLQ-C30 GHS–quality of life (QoL), physical functioning, cognitive functioning, fatigue, and pain; QLQ-MY20 disease symptoms and side effects of treatment; and five-level EQ-5D (EQ-5D-5L) index score and EQ-5D visual VAS. Differences in overall least-squares mean changes from baseline to month 20 were analysed using post-hoc constrained longitudinal data analysis. Time to confirmed improvement or deterioration from baseline was analysed using Cox proportional hazard models. Findings Patients were randomly assigned between May 6, 2019, and April 8, 2022. Overall, the median age was 63 years (IQR 55–68); 151 (39%) patients were female; and 250 (65%) patients were White, 36 (9%) Black or African American, 19 (5%) Hispanic or Latino, 12 (3%) Asian, and seven (2%) of other race. The median follow-up was 18·6 months (IQR 14·0–26·4). PRO compliance was higher than 75% throughout. Overall least-squares mean changes from baseline favoured ide-cel with Hedges' g effect sizes from 0·3 to 0·7 for most domains. Patients in the ide-cel group showed statistically significant and clinically meaningful improvements across the primary PRO domains of interest, with the exception of QLQ-MY20 disease symptoms, side effects of treatment, and EQ-5D-5L index score, which showed improvement across assessment visits but did not exceed the within-group minimally important difference thresholds. The ide-cel group had shorter times to clinically meaningful improvement than the standard regimens group in QLQ-C30 domains except in role functioning, diarrhoea, and financial difficulties; in QLQ-MY20 domains except body image; and in EQ-5D-VAS. Interpretation Ide-cel offers improved health-related quality of life compared with standard regimens for patients with relapsed and refractory multiple myeloma after previous lines of therapy. The PRO data highlight the extended QoL benefits of a one-time infusion with ide-cel compared with continuous treatment with standard regimens in the treatment of triple-class exposed patients with relapsed and refractory multiple myeloma. Funding 2seventy bio and Celgene, a Bristol Myers Squibb Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
英姑的应助被Threeeeeee采纳,获得10
刚刚
石榴姐姐完成签到,获得积分10
1秒前
Twila完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
3秒前
大个的应助被刘星雨采纳,获得10
3秒前
hujiaodawang发布了新的文献求助10
5秒前
XA发布了新的文献求助10
5秒前
5秒前
论文通发布了新的文献求助10
5秒前
7秒前
7秒前
田様的应助被Threeeeeee采纳,获得10
7秒前
yang111完成签到,获得积分10
8秒前
碧蓝白秋发布了新的文献求助10
8秒前
8秒前
缓慢寒梅完成签到,获得积分10
9秒前
Akim的应助被快乐的语海采纳,获得10
9秒前
希望天下0贩的0的应助被LELE采纳,获得10
9秒前
希妍发布了新的文献求助10
10秒前
leo完成签到 ,获得积分10
10秒前
秋风的应助被元气马采纳,获得10
11秒前
11秒前
11秒前
MJMO完成签到,获得积分10
12秒前
尊敬的灰狼完成签到 ,获得积分10
12秒前
体贴问儿完成签到,获得积分10
13秒前
Bay完成签到,获得积分10
13秒前
bkagyin的应助被论文通采纳,获得10
13秒前
张火火完成签到,获得积分10
13秒前
13秒前
14秒前
luyue9406的应助被飘逸的语海采纳,获得10
14秒前
liu.lzy完成签到,获得积分10
14秒前
皮蛋廋肉粥完成签到,获得积分10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168068
求助须知:如何正确求助?哪些是违规求助? 9561081
关于积分的说明 21759342
捐赠科研通 7759355
什么是DOI,文献DOI怎么找? 3429909
关于科研通互助平台的介绍 2553742
邀请新用户注册赠送积分活动 2474451